Financials in USD. Standardized financial statements.
A compact view of how Stoke Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $184.42M | $36.55M | $8.78M | $12.40M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +404.5% | +316.3% | -29.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $1.93M | $450,000 | $214,000 | $113,000 |
| Gross Profit? | $184.42M | $36.55M | $8.78M | $12.40M | $0 | -$1.93M | -$450,000 | -$214,000 | -$113,000 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $205.01M | $137.93M | $123.55M | $116.76M | $86.06M | $51.12M | $35.23M | $12.78M | $5.55M |
| Operating Income? | -$20.59M | -$101.37M | -$114.77M | -$104.36M | -$86.06M | -$53.04M | -$35.68M | -$12.78M | -$5.55M |
| EBITDA? | -$18.82M | -$99.19M | -$112.30M | -$102.81M | -$85.09M | -$50.32M | -$31.88M | -$12.57M | -$5.44M |
| Income Before Tax | -$6.88M | -$88.98M | -$104.70M | -$101.07M | -$85.81M | -$52.24M | -$32.33M | -$12.52M | -$5.56M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$6.88M | -$88.98M | -$104.70M | -$101.07M | -$85.81M | -$52.24M | -$32.33M | -$12.52M | -$5.56M |
| EPS? | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 | $-1.56 | $-1.59 | $-0.53 | $-0.24 |
| Diluted EPS? | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 | $-1.56 | $-1.59 | $-0.53 | $-0.24 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality